| 24.65 0.39 (1.61%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.68 | 1-year : | 32.69 |
| Resists | First : | 26.26 | Second : | 27.98 |
| Pivot price | 24.83  |
|||
| Supports | First : | 23.47 | Second : | 19.53 |
| MAs | MA(5) : | 24.11  |
MA(20) : | 25.35 |
| MA(100) : | 27.48 |
MA(250) : | 28.19 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 20.7 |
D(3) : | 14.6 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 33.7 | Low : | 22.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALKS ] has closed above bottom band by 45.3%. Bollinger Bands are 13.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.8 - 24.89 | 24.89 - 24.97 |
| Low: | 24.01 - 24.12 | 24.12 - 24.22 |
| Close: | 24.47 - 24.63 | 24.63 - 24.77 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Wed, 24 Apr 2024
Alkermes (ALKS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Wed, 24 Apr 2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy ... - PR Newswire
Mon, 22 Apr 2024
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? - Zacks Investment Research
Thu, 11 Apr 2024
Oversold Conditions For Alkermes (ALKS) - Nasdaq
Wed, 10 Apr 2024
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Tue, 09 Apr 2024
Alkermes: Collecting The Fruits Of The 2023 Spinoff (NASDAQ:ALKS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 169 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 107.8 (%) |
| Shares Short | 14,340 (K) |
| Shares Short P.Month | 13,020 (K) |
| EPS | 3.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | 21.3 % |
| Operating Margin | 14.4 % |
| Return on Assets (ttm) | 12.8 % |
| Return on Equity (ttm) | 46.2 % |
| Qtrly Rev. Growth | 23.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.81 |
| EBITDA (p.s.) | 2.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 401 (M) |
| Levered Free Cash Flow | 204 (M) |
| PE Ratio | 8.05 |
| PEG Ratio | 0.3 |
| Price to Book value | 3.42 |
| Price to Sales | 2.51 |
| Price to Cash Flow | 10.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|